Analysts Set GeoVax Labs, Inc. (NASDAQ:GOVX) Price Target at $11.10

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been given an average recommendation of “Buy” by the seven research firms that are presently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $11.10.

A number of research firms have recently weighed in on GOVX. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a research note on Wednesday, April 16th. Alliance Global Partners dropped their price objective on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating for the company in a research note on Tuesday, April 15th. Finally, D. Boral Capital dropped their price objective on GeoVax Labs from $14.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, May 2nd.

GeoVax Labs Stock Down 2.3%

NASDAQ GOVX opened at $1.05 on Friday. The firm has a market cap of $15.89 million, a price-to-earnings ratio of -0.29 and a beta of 3.47. The business has a 50-day moving average price of $1.00 and a 200-day moving average price of $1.69. GeoVax Labs has a twelve month low of $0.73 and a twelve month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.14. The business had revenue of $1.64 million during the quarter, compared to the consensus estimate of $0.75 million. Research analysts expect that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

A number of hedge funds have recently made changes to their positions in GOVX. Jane Street Group LLC purchased a new stake in shares of GeoVax Labs in the first quarter worth about $27,000. Northern Trust Corp purchased a new stake in shares of GeoVax Labs in the fourth quarter worth about $29,000. Citadel Advisors LLC purchased a new stake in shares of GeoVax Labs in the fourth quarter worth about $104,000. Geode Capital Management LLC lifted its position in shares of GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after buying an additional 33,440 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of GeoVax Labs in the first quarter worth about $703,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.